8-K: Regeneron Q3 2025: Dupixent Soars, EYLEA Declines

Regeneron Pharmaceuticals reported a 1% revenue increase to $3.75 billion in Q3 2025, driven by strong Dupixent sales, while EYLEA U.S. sales significantly decreased and EYLEA HD faced a manufacturing-related regulatory setback.

Summary

• Total revenues for Q3 2025 increased by 1% to $3.75 billion compared to Q3 2024.
• GAAP net income rose 9% to $1.46 billion, with GAAP diluted EPS increasing 18% to $13.62.
• Non-GAAP net income decreased 12% to $1.29 billion, and non-GAAP diluted EPS fell 5% to $11.83, partly due to an unfavorable $0.68 impact from an acquired IPR&D charge.
• Dupixent global net sales, recorded by Sanofi, surged 27% to $4.86 billion.
• EYLEA HD U.S. net sales grew 10% to $431 million, but total EYLEA HD and EYLEA U.S. net sales decreased 28% to $1.11 billion, primarily due to a 41% drop in EYLEA U.S. sales.
• Libtayo global net sales increased 26% to $365 million.
• The FDA approved Libtayo as the first and only immunotherapy for high-risk adjuvant cutaneous squamous cell carcinoma (CSCC).
• The FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe supplemental Biologics License Application (sBLA) due to unresolved manufacturing inspection findings at Catalent.
• Positive Phase 3 results were reported for trials in generalized myasthenia gravis (cemdisiran), fibrodysplasia ossificans progressiva (FOP) (garetosmab), and cat and birch allergies.
• Updated positive data from the pivotal trial of DB-OTO in children with profound genetic hearing loss showed clinically meaningful hearing improvements in 11 out of 12 participants.
• Regeneron resolved patent infringement litigation related to EYLEA biosimilar products, precluding their U.S. launch until Q4 2026.
• The company repurchased $663 million of common stock in Q3 2025 and declared a cash dividend of $0.88 per share.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there are strong positives like Dupixent's growth, multiple pipeline advancements, and new approvals, the significant decline in EYLEA sales and the regulatory setback for EYLEA HD's pre-filled syringe due to manufacturing issues introduce notable concerns. The overall financial performance is mixed, with GAAP metrics up but non-GAAP metrics down. The resolution of biosimilar litigation is a clear positive, but the EYLEA franchise faces ongoing challenges.

Positives

• Total revenues increased by 1% to $3.75 billion in Q3 2025.
• GAAP net income increased 9% to $1.46 billion, and GAAP diluted EPS increased 18% to $13.62.
• Dupixent global net sales (recorded by Sanofi) increased significantly by 27% to $4.86 billion.
• EYLEA HD U.S. net sales increased 10% to $431 million due to higher sales volumes and increased demand.
• Libtayo global net sales increased 26% to $365 million, with U.S. sales up 12% and Rest of World sales up 55%.
• Praluent U.S. net sales increased 26% to $67 million.
• Evkeeza U.S. net sales increased 34% to $43 million.
• FDA approved Libtayo as the first and only immunotherapy for high-risk adjuvant cutaneous squamous cell carcinoma (CSCC).
• EMA's CHMP adopted a positive opinion for Libtayo in adjuvant CSCC and for Dupixent in chronic spontaneous urticaria (CSU).
• Japan's MHLW approved Libtayo for unresectable advanced or relapsed non-small cell lung cancer (NSCLC).
• Five-year follow-up data for Libtayo in NSCLC showed a more than double five-year overall survival rate of 19.4% compared to 8.8% with chemotherapy alone.
• Positive Phase 3 results for cemdisiran in generalized myasthenia gravis, with U.S. regulatory submission planned for Q1 2026.
• Updated positive data for DB-OTO gene therapy in profound genetic hearing loss, showing clinically meaningful improvements in 11 out of 12 participants.
• FDA selected DB-OTO to receive one of the Commissioner's National Priority Vouchers, expediting its review time.
• Positive Phase 3 results for garetosmab in fibrodysplasia ossificans progressiva (FOP), showing a >90% reduction in new bone lesions, with U.S. regulatory submission planned for Q4 2025.
• FDA approved Evkeeza for homozygous familial hypercholesterolemia (HoFH), extending the indication to children aged 1 to less than 5 years old.
• Phase 3 trials for allergen-blocking antibodies in cat and birch allergies met primary and key secondary endpoints.
• Resolution of EYLEA biosimilar patent infringement litigation, precluding U.S. launch by Sandoz, Formycon, and Celltrion until Q4 2026.
• The company repurchased $663 million of common stock in Q3 2025, demonstrating commitment to shareholder value.
• Increased other revenue by 74% to $198 million, driven by higher royalties and license agreement profits.
• Net gains on marketable and other securities increased to $578 million in Q3 2025 from $135 million in Q3 2024.

Negatives

• Non-GAAP net income decreased 12% to $1.29 billion, and non-GAAP diluted EPS decreased 5% to $11.83.
• Total EYLEA HD and EYLEA U.S. net sales decreased 28% to $1.11 billion.
• EYLEA U.S. net sales decreased significantly by 41% to $681 million, impacted by competitive pressures, loss of market share to compounded bevacizumab, patient transition to EYLEA HD, and a lower net selling price.
• Total net product sales decreased 18% to $1.59 billion.
• FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe sBLA due to unresolved inspection findings at Catalent, a manufacturing filler.
• GAAP gross margin on net product sales decreased to 82% from 87%, partly due to ongoing manufacturing investments and higher amortization expense for the Libtayo intangible asset.
• Bayer collaboration revenue decreased 12% to $345 million.
• GAAP effective tax rate increased to 17.2% from 10.2%, primarily due to a $45 million charge related to the enactment of the 'One Big Beautiful Bill Act' (OBBBA) and lower tax benefits from stock option exercises.

Risks

• Competing drugs and product candidates may be superior or more cost-effective than Regeneron's products and candidates.
• Uncertainty regarding the utilization, market acceptance, and commercial success of Regeneron's products and product candidates.
• Safety issues, serious complications, or side effects from the administration of Regeneron's products and product candidates in patients or clinical trials.
• Delays or restrictions in development or commercialization due to determinations by regulatory and administrative governmental authorities.
• Ability to manufacture and manage supply chains for multiple products and product candidates, including risks associated with tariffs and trade restrictions.
• Reliance on collaborators, suppliers, or other third parties (e.g., Catalent for EYLEA HD) to perform manufacturing, filling, packaging, and distribution steps.
• Availability and extent of reimbursement or copay assistance for Regeneron's products from third-party payors and government programs.
• Changes to drug pricing regulations and requirements and Regeneron's drug pricing strategy.
• Unanticipated expenses and the costs of developing, producing, and selling products.
• Potential for license or collaboration agreements (e.g., with Sanofi and Bayer) to be cancelled or terminated.
• Impact of public health outbreaks, epidemics, or pandemics on Regeneron's business.
• Risks associated with litigation and other proceedings and government investigations (e.g., U.S. Department of Justice, patent litigation related to EYLEA).

Future Outlook

Regeneron updated its full-year 2025 financial guidance, adjusting GAAP R&D to $5.680-$5.750 billion and non-GAAP R&D to $5.150-$5.200 billion. GAAP SG&A is now projected at $2.775-$2.845 billion, and non-GAAP SG&A at $2.400-$2.450 billion. The GAAP gross margin on net product sales is expected to be approximately 82%, while the non-GAAP gross margin remains unchanged at approximately 86%. COCM guidance is $950 million-$1.000 billion, and capital expenditures are $850-$890 million. The GAAP effective tax rate is anticipated to be approximately 14%, and the non-GAAP effective tax rate approximately 12%. The company plans U.S. regulatory submissions for DB-OTO and garetosmab in Q4 2025, and for cemdisiran monotherapy in Q1 2026. An application for a new EYLEA HD pre-filled syringe manufacturing filler is planned for submission by January 2026, with an FDA decision on an additional vial filler expected by late December 2025. Additional Phase 3 development for allergen-blocking antibodies is planned by year-end.

Management Comments

• "Regeneron had a solid financial quarter and made progress across our late-stage portfolio by securing new FDA approvals for Libtayo, Evkeeza, and Lynozyfic, receiving positive CHMP opinions for Libtayo and Dupixent, and sharing promising data across our oncology, obesity, allergy, and rare disease portfolios." Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer.
• "We were proud to receive one of the FDAs first Commissioner's National Priority Vouchers for DB-OTO for a rare form of congenital hearing loss. We also donated our Ebola treatment, Inmazeb, to countries most at risk of outbreaks, reflecting our commitment to ensuring patients in need are able to access our novel medicines." Leonard S. Schleifer, M.D., Ph.D.
• "We were pleased with our third quarter 2025 performance, which highlights the commercial strength of Dupixent, EYLEA HD, and Libtayo, and reinforces our momentum toward delivering solid financial performance for the year while advancing transformative therapies to patients around the world." Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer.
• "Our disciplined approach to capital allocation fuels innovation through targeted investments, all while delivering value to shareholders. In the first nine months of 2025, we reaffirmed our commitment to advancing U.S. innovation and manufacturing by investing nearly $5 billion in R&D and capital expenditures, predominantly within the United States. We also returned over $3 billion to shareholders via share repurchases and dividends, underscoring our commitment to long-term value creation." Christopher Fenimore.

Industry Context

Regeneron's Q3 2025 results reflect a dynamic pharmaceutical landscape. The strong growth of Dupixent underscores its continued market dominance in allergic and inflammatory diseases, aligning with broader industry trends of increasing demand for biologics in these areas. The decline in EYLEA sales highlights intense competition in the ophthalmology market, particularly from biosimilars and lower-cost alternatives like compounded bevacizumab, a challenge many established blockbuster drugs face. The regulatory setback for EYLEA HD's pre-filled syringe due to manufacturing issues at a third-party filler emphasizes the critical importance of supply chain robustness and quality control in the highly regulated biotech sector. Meanwhile, the numerous positive clinical trial readouts and new approvals for Libtayo, Evkeeza, and pipeline candidates like DB-OTO and garetosmab demonstrate Regeneron's strong R&D engine and diversified pipeline, positioning it for future growth in oncology, rare diseases, and gene therapy, areas of significant innovation and investment across the industry.

Comparison to Industry Standards

• The 27% increase in Dupixent global net sales to $4.86 billion demonstrates strong market penetration and competitive performance, comparable to other leading biologics in immunology such as Humira (AbbVie) or Stelara (Johnson & Johnson) in their growth phases, though specific direct comparisons are not provided in the filing.
• The 41% decrease in EYLEA U.S. net sales to $681 million, attributed to competitive pressures and loss of market share to compounded bevacizumab, indicates a significant challenge in the ophthalmology market. This trend is consistent with the broader industry experience where established biologics face erosion from biosimilars and off-label use of cheaper alternatives, similar to the impact of biosimilars on Remicade (Johnson & Johnson) or Neulasta (Amgen).
• The FDA's Complete Response Letter (CRL) for EYLEA HD's pre-filled syringe sBLA due to manufacturing issues at Catalent is a common regulatory hurdle in the pharmaceutical industry, where third-party manufacturing quality can impact approval timelines. This is not unique to Regeneron and has been observed with other companies relying on contract manufacturing organizations (CMOs).
• The five-year overall survival rate of 19.4% for Libtayo plus chemotherapy in NSCLC, compared to 8.8% with chemotherapy alone, represents a clinically meaningful improvement, positioning Libtayo competitively against other PD-1 inhibitors like Keytruda (Merck) and Opdivo (Bristol Myers Squibb) in this indication, although direct head-to-head efficacy comparisons are not detailed.
• The positive Phase 3 results for DB-OTO gene therapy in profound genetic hearing loss, with 11 out of 12 participants showing clinically meaningful hearing improvements, are highly promising and align with the cutting-edge advancements seen in the gene therapy space, comparable to the early successes of therapies like Luxturna (Spark Therapeutics) for inherited retinal disease or Zolgensma (Novartis) for spinal muscular atrophy.

Legal Proceedings

• Resolution of patent infringement litigation related to the Sandoz, Formycon, and Celltrion EYLEA (aflibercept) Injection 2 mg biosimilar products, precluding their U.S. launch until Q4 2026.
• All intellectual property-related litigation with Sandoz, Formycon, and Celltrion in the United States has been dismissed.
• Forward-looking statements mention risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), and risks associated with intellectual property of other parties and pending or future litigation thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA).

Stakeholder Impact

• **Shareholders:** Mixed financial results with strong growth in key products (Dupixent, Libtayo) offset by significant decline in EYLEA sales and a regulatory setback for EYLEA HD. Share repurchases and dividends demonstrate commitment to shareholder returns. Resolution of EYLEA biosimilar litigation provides clarity and extends market exclusivity.
• **Patients:** New FDA approvals for Libtayo (CSCC) and Evkeeza (HoFH in younger children) expand treatment options. Positive clinical trial data for DB-OTO (hearing loss), cemdisiran (myasthenia gravis), and garetosmab (FOP) offer hope for new therapies. The delay in EYLEA HD pre-filled syringe availability due to manufacturing issues could impact patient access to a convenient formulation.
• **Employees:** Continued investment in R&D and manufacturing, predominantly in the U.S., supports job stability and growth opportunities within the company.
• **Customers (Healthcare Providers):** Expanded indications for Libtayo and Evkeeza provide more tools for patient care. The EYLEA HD pre-filled syringe delay might cause inconvenience or require alternative administration methods.
• **Suppliers/Partners:** The manufacturing issue at Catalent highlights the critical role of third-party suppliers and the need for robust quality control. Collaboration revenues with Sanofi increased due to Dupixent's success, while Bayer collaboration revenue decreased, reflecting varying performance across partnerships.

Next Steps

• European Commission (EC) final decision expected in coming months for Dupixent in chronic spontaneous urticaria (CSU).
• Company planning to submit an application to include a new pre-filled syringe manufacturing filler in the EYLEA HD BLA by January 2026.
• FDA target action date in late November 2025 for sBLA for EYLEA HD every-four-week dosing and for the treatment of macular edema following retinal vein occlusion (RVO).
• FDA decision regarding an additional EYLEA HD vial filler expected by late December 2025.
• European Commission (EC) final decision expected in coming months for Libtayo in adjuvant CSCC.
• U.S. regulatory submission for cemdisiran monotherapy planned for the first quarter of 2026, pending discussions with the FDA.
• U.S. regulatory submission for DB-OTO planned for the fourth quarter of 2025.
• U.S. regulatory submission for garetosmab planned for the fourth quarter of 2025.
• Additional Phase 3 development for allergen-blocking antibodies planned to begin by the end of 2025.
• Conference call and webcast to discuss Q3 2025 results on October 28, 2025, at 8:30 AM Eastern Time.

Key Dates

Recommendation

The filing presents a mixed picture. Strong growth in Dupixent and Libtayo, coupled with multiple positive pipeline advancements and new approvals, demonstrates Regeneron's robust R&D and commercial capabilities. The resolution of EYLEA biosimilar litigation provides a temporary reprieve. However, the significant decline in EYLEA U.S. sales due to competitive pressures and the manufacturing-related Complete Response Letter (CRL) for EYLEA HD's pre-filled syringe are notable concerns. While GAAP earnings improved, non-GAAP earnings declined. The company's updated guidance reflects these dynamics. Given the strong pipeline and growth drivers balanced against the challenges in the EYLEA franchise and manufacturing issues, a 'hold' recommendation is appropriate. Investors should monitor the resolution of the EYLEA HD manufacturing issue and the continued performance of the EYLEA franchise against new competition, while appreciating the long-term potential of the diversified pipeline.

Keywords

Regeneron, REGN, Pharmaceuticals, Biotechnology, Dupixent, EYLEA HD, EYLEA, Libtayo, Cemiplimab, Aflibercept, Dupilumab, Oncology, Ophthalmology, Immunology, Rare Disease, Gene Therapy, DB-OTO, CSCC, NSCLC, Myasthenia Gravis, FOP, Allergies, FDA Approval, CHMP Opinion, Clinical Trials, Financial Results, Q3 2025, SEC Filing, 8-K, Biologics, Drug Development, Patent Litigation, Biosimilar